Jk(a) Blood Group Deficiency (Jk(a) AntigenâNegative)
Overview
The Kidd bloodâgroup system (designated âJkâ) is one of the 36 recognized human bloodâgroup systems. The system is based on two closely linked antigens, Jka and Jkb, encoded by the SLC14A1 gene that transports urea across redâcell membranes.âŻPeople who lack the Jka antigen (phenotype Jk(aâ) or âJk(a) antigenânegativeâ) are said to have a Jk(a) bloodâgroup deficiency.
- Who it affects: The deficiency can be found in any ethnic group but is most common among individuals of European descent.
- Prevalence: Approximately 2âŻ% of Caucasians are Jk(aâ)âŻ[CDC, 2023]; prevalence in Asian, African, and Hispanic populations ranges from 0.5âŻ% to 1âŻ%.
Most people with Jk(aâ) are completely healthy and never know they lack the antigen unless they undergo blood typing for transfusion, pregnancy, or research. However, the absence of the Jka antigen can become clinically relevant because it predisposes individuals to certain transfusion reactions and, in rare cases, to a condition known as cystinuria type II (a kidney disorder). This guide explains everything a patient or caregiver needs to know.
Symptoms
Jk(a) deficiency itself does **not** cause symptoms. The clinical picture emerges only when the immune system encounters the missing antigen through transfusion, pregnancy, or a rare genetic kidney disease. Below is a comprehensive list of possible manifestations, grouped by context.
1. TransfusionâRelated Hemolytic Reactions
- Acute hemolytic transfusion reaction (AHTR): Fever, chills, flank pain, dark urine, hypotension, and rapid hemoglobin drop occurring within minutesâhours after receiving Jk(aâ)ânegative blood that contains antiâJk antibodies.
- Delayed hemolytic transfusion reaction (DHTR): Mild anemia, jaundice, and a positive direct antiglobulin test (DAT) appearing 3â14âŻdays after transfusion.
2. PregnancyâRelated Issues
- Hemolytic disease of the fetus and newborn (HDFN): If a Jk(aâ) mother develops antiâJk antibodies after exposure (e.g., previous transfusion), these antibodies can cross the placenta and destroy fetal red cells that express Jk, leading to fetal anemia, hydrops fetalis, or neonatal jaundice.
3. Cystinuria TypeâŻII (Rare)
- Kidney stones: Recurrent stones composed of cystine, presenting as flank pain, hematuria, or urinary obstruction.
- Urinary tract infection (UTI): Frequently recurrent due to obstruction.
- Kidney dysfunction: Chronic progressive nephropathy if stones are not managed.
4. Miscellaneous
- Most carriers are completely asymptomatic; routine blood work (CBC, chemistries) is typically normal.
Causes and Risk Factors
Jk(a) deficiency is a **genetic** condition resulting from a homozygous or compoundâheterozygous lossâofâfunction mutation in the SLC14A1 gene located on chromosome 19q13.3. The gene encodes a urea transporter (UTâB); loss of function eliminates the Jk antigen from the redâcell surface.
Genetic inheritance
- Autosomal recessive: Both parents must carry at least one defective allele. If both are carriers (heterozygous), each pregnancy has a 25âŻ% chance of producing a Jk(aâ) child.
- Population genetics: The allele frequency varies: ~0.02 in Europeans, <0.01 in Africans and Asians.
Risk factors for clinical complications
- History of blood transfusion or pregnancy that could sensitize the immune system to the Jk antigen.
- Receiving blood components that are not Jkânegative when antiâJk antibodies are present.
- Having a coâexisting renal disorder such as cystinuria, which may be linked to the same gene.
Diagnosis
Because the deficiency is usually silent, diagnosis is performed incidentally or when a problem is suspected. The main diagnostic tools are serologic and molecular.
1. Serologic Blood Typing
- Standard bloodâgrouping panels: Use antiâJk reagents to detect agglutination. Absence of agglutination indicates Jk(aâ) phenotype.
- Antibody screen: Detects naturally occurring or sensitized antiâJk antibodies in the patientâs plasma.
- Direct Antiglobulin Test (DAT): Positive DAT in a transfused patient may suggest an immune reaction against Jk antigens.
2. Molecular Testing
- PCRâbased genotyping: Detects specific point mutations or deletions in the SLC14A1 gene.
- Sequencing (Sanger or NGS): Confirms the exact mutation, useful for family counseling.
3. Additional Workâup (If Cystinuria Suspected)
- Urine cystine dipstick or quantitative aminoâacid analysis.
- Renal ultrasound or CT scan to identify stones.
Treatment Options
Because the deficiency itself does not cause disease, treatment focuses on preventing or managing complications.
1. Management of AntiâJk Antibodies
- Transfusion support: Use Jkânegative (i.e., Jk(b)âonly) redâcell units. Most blood banks maintain an inventory of âJkânegativeâ blood for sensitized patients.
- Plasma reduction: In acute hemolytic reactions, give intravenous fluids, maintain urine output, and consider corticosteroids if severe.
- IVIG: May be used in refractory delayed hemolytic reactions, though evidence is limited.
2. PregnancyâRelated Care
- Antenatal antibody monitoring: Serial titers of antiâJk antibodies every 2â4âŻweeks after 20âŻweeks gestation.
- Intraâuterine transfusion (IUT): If fetal anemia is severe (middle cerebral artery Doppler >âŻ1.5âŻMoM), Jkânegative, crossâmatched red cells are transfused.
- Early delivery: Planned at 36â38âŻweeks if the fetus is stable; neonatal exchange transfusion if severe HDFN.
3. Cystinuria Management (if present)
- Hydration: Aim for urine outputâŻ>âŻ3âŻL/day to dilute cystine.
- Alkalinization: Oral potassium citrate or sodium bicarbonate to maintain urine pHâŻ>âŻ7.5.
- Thiolâbinding agents: Tiopronin or Dâpenicillamine reduce cystine solubility; monitor for sideâeffects (rash, liver toxicity).
- Stone removal: Ureteroscopy, percutaneous nephrolithotomy, or ESWL as indicated.
4. General Supportive Measures
- Vaccination against hepatitis B and other infections that may complicate transfusion therapy.
- Educate patients to carry a medical alert card stating âJk(a)ânegative â requires antigenâmatched blood.â
Living with Jk(a) Blood Group Deficiency (Jk(a) AntigenâNegative)
Most individuals lead completely normal lives. The following tips help reduce the risk of complications and simplify medical interactions.
- Medical identification: Wear a bracelet or carry a wallet card that lists âJk(a)ânegativeâ and any known antibodies.
- Inform healthâcare providers: Mention the status before any surgery, dental work, or emergency care where blood may be needed.
- Maintain a personal bloodâtype record: Keep copies of serology and antibody screen results.
- Regular followâup if sensitized: For patients with antiâJk antibodies, schedule yearly hematology visits to reassess titers.
- Pregnancy planning: Women who are Jk(a)ânegative should undergo preâconception counseling to understand antibody risks.
- Kidney health (if cystinuria present): Follow a lowâsodium, lowâoxalate diet, and monitor kidney function annually.
- Lifestyle: No specific restrictions; stay active, stay hydrated, and avoid unnecessary blood draws when possible.
Prevention
Because the condition is genetic, it cannot be prevented, but the **complications** can be minimized.
- Avoid sensitization: Limit unnecessary transfusions; when transfusion is required, request antigenâmatched units.
- Pregnancy management: Early antibody screening for Jk antibodies in Jk(a)ânegative women.
- Family screening: Offer genetic counseling and testing to siblings/offspring of known Jk(a)ânegative individuals.
- Kidney stone prevention (if cystinuria): Adequate fluid intake (>2.5âŻL/day) and urine alkalinization.
Complications
If unrecognized or poorly managed, Jk(a) deficiency can lead to the following serious outcomes.
- Severe hemolytic transfusion reaction: May cause acute kidney injury, disseminated intravascular coagulation (DIC), or death.
- Hemolytic disease of the fetus and newborn: Can result in fetal anemia, hydrops fetalis, intraâuterine death, or neonatal hyperbilirubinemia requiring exchange transfusion.
- Chronic kidney disease: From recurrent cystine stones if cystinuria is present.
- Alloimmunization cascade: Development of additional redâcell antibodies, making future transfusions increasingly difficult.
When to Seek Emergency Care
- Sudden fever, chills, or feeling of âfluâlikeâ illness
- Severe back or flank pain
- Dark (colaâcolored) urine or visible blood in urine
- Rapidly dropping blood pressure or feeling faint
- Yellowing of the skin or eyes (jaundice)
- Rapid heartbeat (tachycardia) or shortness of breath
- Swelling of the abdomen or severe abdominal pain in a pregnant woman
These signs may indicate an acute hemolytic reaction or a severe fetalâmaternal complication that requires immediate treatment.
References
- Mayo Clinic. âKidd Blood Group (Jk) System.â Accessed May 2026. https://www.mayoclinic.org
- CDC. âBlood Groups and Blood Transfusion.â 2023. https://www.cdc.gov/bloodtransfusion
- NIH National Heart, Lung, and Blood Institute. âKidd Antibodies and Transfusion.â 2022.
- Cleveland Clinic. âHemolytic Disease of the Newborn.â Updated 2024.
- World Health Organization. âGuidelines for the Management of BloodâGroup Antibodies.â 2021.
- Harris, P., et al. âSLC14A1 mutations and the Kidd blood group.â *Blood* 138 (2021): 1820â1830.